Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.8 USD | +2.13% |
|
-7.16% | +69.01% |
06-25 | Humacyte, Inc. Presents Positive Preclinical Data for Its Biovascular Pancreas (Bvp??) Program | CI |
06-24 | Humacyte, Inc.(NasdaqGS:HUMA) added to S&P Biotechnology Select Industry Index | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+69.01% | 572M | |
+19.41% | 45.51B | |
+38.65% | 39.36B | |
-8.62% | 38.52B | |
+26.95% | 30.74B | |
-13.50% | 26.03B | |
+10.74% | 25.92B | |
+44.87% | 14.13B | |
+34.36% | 12.73B | |
-7.14% | 11.29B |
- Stock Market
- Equities
- HUMA Stock
- News Humacyte, Inc.
- Humacyte Insider Sold Shares Worth $4,520,024, According to a Recent SEC Filing